HK1249031A1 - 疫苗施用的方法 - Google Patents

疫苗施用的方法

Info

Publication number
HK1249031A1
HK1249031A1 HK18108747.9A HK18108747A HK1249031A1 HK 1249031 A1 HK1249031 A1 HK 1249031A1 HK 18108747 A HK18108747 A HK 18108747A HK 1249031 A1 HK1249031 A1 HK 1249031A1
Authority
HK
Hong Kong
Prior art keywords
methods
vaccine administration
vaccine
administration
Prior art date
Application number
HK18108747.9A
Other languages
English (en)
Inventor
John David Haworth
Cassius Mcallister Tucker
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39609100&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1249031(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of HK1249031A1 publication Critical patent/HK1249031A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/175—Canine distemper virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18471—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
HK18108747.9A 2006-12-27 2018-07-06 疫苗施用的方法 HK1249031A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87732206P 2006-12-27 2006-12-27

Publications (1)

Publication Number Publication Date
HK1249031A1 true HK1249031A1 (zh) 2018-10-26

Family

ID=39609100

Family Applications (4)

Application Number Title Priority Date Filing Date
HK10100622.4A HK1134243A1 (zh) 2006-12-27 2010-01-21 適用於治療犬的犬病的疫苗
HK15101146.4A HK1200374A1 (zh) 2006-12-27 2015-02-03 疫苗施用的方法
HK15101144.6A HK1200372A1 (zh) 2006-12-27 2015-02-03 疫苗施用的方法
HK18108747.9A HK1249031A1 (zh) 2006-12-27 2018-07-06 疫苗施用的方法

Family Applications Before (3)

Application Number Title Priority Date Filing Date
HK10100622.4A HK1134243A1 (zh) 2006-12-27 2010-01-21 適用於治療犬的犬病的疫苗
HK15101146.4A HK1200374A1 (zh) 2006-12-27 2015-02-03 疫苗施用的方法
HK15101144.6A HK1200372A1 (zh) 2006-12-27 2015-02-03 疫苗施用的方法

Country Status (25)

Country Link
US (4) US20100028379A1 (zh)
EP (5) EP3300743B1 (zh)
JP (1) JP5762664B2 (zh)
KR (1) KR101099883B1 (zh)
CN (1) CN101573137B (zh)
AR (1) AR064530A1 (zh)
AU (1) AU2007343130C1 (zh)
BR (1) BRPI0720667A8 (zh)
CA (1) CA2674026C (zh)
CY (1) CY1120015T1 (zh)
DK (2) DK2762163T3 (zh)
ES (2) ES2660035T3 (zh)
FI (1) FI3300743T3 (zh)
HK (4) HK1134243A1 (zh)
HU (2) HUE036174T2 (zh)
LT (1) LT2762163T (zh)
MX (1) MX2009007087A (zh)
NZ (1) NZ577855A (zh)
PL (2) PL2762163T3 (zh)
PT (1) PT2762163T (zh)
SI (1) SI2762163T1 (zh)
TR (1) TR201802917T4 (zh)
TW (1) TW200833354A (zh)
WO (1) WO2008084294A2 (zh)
ZA (1) ZA200904756B (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050089533A1 (en) * 2003-01-29 2005-04-28 Joseph Frantz Canine vaccines against Bordetella bronchiseptica
EP3300743B1 (en) * 2006-12-27 2023-06-14 Zoetis Services LLC Methods of vaccine administration
US8877201B2 (en) * 2007-10-25 2014-11-04 Wake Forest University Health Sciences Bordetella outer-membrane protein antigens and methods of making and using the same
EP2453916A4 (en) * 2009-07-17 2013-06-05 Univ Oklahoma State SUPRALINGUAL VACCINES AND SUPRALINGUAL APPLICATORS
US20110229516A1 (en) * 2010-03-18 2011-09-22 The Clorox Company Adjuvant phase inversion concentrated nanoemulsion compositions
CN101914502B (zh) * 2010-07-30 2012-01-11 中国农业科学院哈尔滨兽医研究所 Ⅰ型犬腺病毒弱毒疫苗株及其应用
US20120107354A1 (en) * 2010-10-30 2012-05-03 George Dacai Liu Viral vaccine and process for preparing the same
DK2646052T3 (en) 2010-12-02 2017-07-17 Oncolytics Biotech Inc LYOPHILIZED VIRAL FORMULATIONS
SG190418A1 (en) 2010-12-02 2013-07-31 Oncolytics Biotech Inc Liquid viral formulations
WO2012124764A1 (ja) 2011-03-17 2012-09-20 国立大学法人三重大学 抗体の製造方法
EA032284B1 (ru) * 2012-05-31 2019-05-31 Зоэтис Ллс Вакцинация респираторным коронавирусом собак для защиты от инфекций в. bronchiseptica
CZ307883B6 (cs) * 2013-01-29 2019-07-24 Bioveta, A.S. Multivalentní vakcína k imunoprofylaxi infekčních onemocnění psů
CN107320720A (zh) * 2016-04-29 2017-11-07 普莱柯生物工程股份有限公司 一种疫苗组合物、试剂盒及应用
CN106591242B (zh) * 2016-11-18 2019-08-30 北京世纪元亨动物防疫技术有限公司 一株犬细小病毒毒株cpv-yh及其应用
MX2019009580A (es) 2017-02-13 2020-01-30 Boehringer Ingelheim Animal Health Usa Inc Aplicador de liquidos para suministrar vacunas.
GB201806460D0 (en) * 2018-04-20 2018-06-06 Secr Defence Pharmaceutical compositions and associated kits

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US5013663A (en) * 1983-06-15 1991-05-07 American Home Products Corporation Canine corona virus vaccine
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
DE3526809A1 (de) * 1985-07-26 1987-04-02 Behringwerke Ag Tollwut-lebendimpfstoff
EP0231039B1 (en) 1986-01-14 1992-01-08 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Process for preparing immunological complexes and pharmaceutical composition containing these complexes
US5019388A (en) * 1986-10-14 1991-05-28 Norden Laboratories Inc. Bordetella bronchiseptica vaccine
US5000951A (en) * 1987-03-09 1991-03-19 Diamond Scientific Company Multivalent canine distemper virus vaccine
US4990367A (en) * 1987-03-09 1991-02-05 Diamond Scientific Company Canine distemper virus vaccine
FR2652501B1 (fr) 1989-10-02 1992-01-10 Rhone Merieux Elements therapeutiques pour l'administration orale d'un medicament aux animaux et procede de fabrication.
US5178862A (en) * 1989-12-01 1993-01-12 Parhelion Corporation Canine distemper virus vaccine and method of preparation
US5757063A (en) * 1994-03-25 1998-05-26 Kabushiki Kaisha Toshiba Semiconductor device having an extrinsic gettering film
CN1117081A (zh) * 1995-03-16 1996-02-21 高云 犬瘟热狂犬病细小病毒三联活疫苗、毒种及制造方法
CN1137347A (zh) * 1995-06-22 1996-12-11 中国人民解放军第四军医大学 犬五联(犬狂犬、犬瘟热、犬细小病毒、犬腺病毒2型、犬副流感)活疫苗
WO1998018453A1 (en) * 1996-10-28 1998-05-07 Pfizer Inc. Oral vaccines for young animals with an enteric coating
US5884583A (en) 1997-03-28 1999-03-23 Rhone Merieux, Inc. Field bag boost vaccination delivery system
WO2001059070A1 (en) 2000-02-12 2001-08-16 Kim Won Yong Production method of recombinant rotavirus structural proteins and vaccine composition
MY128159A (en) * 2000-06-30 2007-01-31 Wyeth Corp Methods and composition for oral vaccination
US20030129161A1 (en) 2001-09-17 2003-07-10 Hsien-Jue Chu Interleukin-12 as a veterinary vaccine adjuvant
US20050089533A1 (en) * 2003-01-29 2005-04-28 Joseph Frantz Canine vaccines against Bordetella bronchiseptica
WO2004067031A1 (en) 2003-01-29 2004-08-12 Pfizer Products Inc. Canine vaccines against bordetella bronchiseptica
MXPA06015263A (es) 2004-06-21 2007-09-27 Merial Ltd Vacunacion de zorrillos y/o mangostas contra rabia.
WO2006014292A2 (en) 2004-07-02 2006-02-09 Dattwyler Raymond J Oral vaccine for borrelia
CA2604488A1 (en) * 2005-04-07 2006-10-12 Pharmacia & Upjohn Company Llc Formulations and process for production of bordetella bronchiseptica p68 antigen and vaccines
EP1945254A1 (en) * 2005-10-07 2008-07-23 Pfizer Products Incorporated Vaccines and methods to treat canine influenza
EP3300743B1 (en) * 2006-12-27 2023-06-14 Zoetis Services LLC Methods of vaccine administration

Also Published As

Publication number Publication date
HK1134243A1 (zh) 2010-04-23
EP3300743A1 (en) 2018-04-04
MX2009007087A (es) 2009-08-12
PL2762163T3 (pl) 2018-05-30
US20100028379A1 (en) 2010-02-04
WO2008084294A2 (en) 2008-07-17
EP4233899A2 (en) 2023-08-30
HUE062920T2 (hu) 2023-12-28
US11524067B2 (en) 2022-12-13
SI2762163T1 (en) 2018-05-31
ES2660035T3 (es) 2018-03-20
WO2008084294A3 (en) 2008-12-31
HUE036174T2 (hu) 2018-06-28
US20200316192A1 (en) 2020-10-08
DK3300743T3 (da) 2023-07-24
TR201802917T4 (tr) 2018-03-21
AU2007343130C1 (en) 2017-11-09
CN101573137A (zh) 2009-11-04
US20230078668A1 (en) 2023-03-16
LT2762163T (lt) 2018-02-26
EP2762163B1 (en) 2018-01-03
KR101099883B1 (ko) 2011-12-28
EP2129392A2 (en) 2009-12-09
HK1200372A1 (zh) 2015-08-07
EP3300743B1 (en) 2023-06-14
JP2008169207A (ja) 2008-07-24
US11524068B2 (en) 2022-12-13
CY1120015T1 (el) 2018-12-12
CA2674026A1 (en) 2008-07-17
CN101573137B (zh) 2014-05-14
BRPI0720667A2 (pt) 2014-01-14
PT2762163T (pt) 2018-02-22
US20150182619A1 (en) 2015-07-02
PL3300743T3 (pl) 2023-09-11
AR064530A1 (es) 2009-04-08
HK1200374A1 (zh) 2015-08-07
NZ577855A (en) 2012-07-27
DK2762163T3 (en) 2018-02-12
JP5762664B2 (ja) 2015-08-12
AU2007343130A1 (en) 2008-07-17
BRPI0720667A8 (pt) 2017-04-25
AU2007343130B2 (en) 2012-12-20
FI3300743T3 (fi) 2023-08-11
ES2951660T3 (es) 2023-10-24
ZA200904756B (en) 2010-05-26
CA2674026C (en) 2018-08-21
EP2762162A1 (en) 2014-08-06
KR20090094393A (ko) 2009-09-04
EP2129392B1 (en) 2013-07-31
EP2762163A1 (en) 2014-08-06
EP4233899A3 (en) 2023-11-08
TW200833354A (en) 2008-08-16

Similar Documents

Publication Publication Date Title
HK1249031A1 (zh) 疫苗施用的方法
GB0607088D0 (en) Vaccine
ZA200808489B (en) Nicotine-carrier vaccine formulation
EP2081591A4 (en) LI-KEY REINFORCED POTENTIAL OF VACCINES
HK1129836A1 (zh) 疫苗
EP2222328A4 (en) PROCESS FOR THE ADMINISTRATION OF CONJUGATES
HRP20180744T1 (hr) Terapeutska cjepiva
IL195618A0 (en) Drug administration methods
ZA200901592B (en) Vaccine
ZA201001477B (en) Methods of enhancing adjuvanticity of vaccine compositions
GB0625593D0 (en) Vaccine
GB0601035D0 (en) Method of vaccine preparation
GB0610095D0 (en) Vaccine formulation
GB0620815D0 (en) Vaccine
GB0614254D0 (en) Vaccine
GB0606256D0 (en) Anti-atheroma vaccine
GB0620337D0 (en) Vaccine
GB0619826D0 (en) Vaccine
GB0619822D0 (en) Vaccine
GB0619821D0 (en) Vaccine
GB0620816D0 (en) vaccine
GB0607087D0 (en) Vaccine
GB0620336D0 (en) Vaccine
GB0619820D0 (en) Vaccine
GB0614476D0 (en) Vaccine